Acrivon Therapeutics (ACRV) Competitors $1.20 -0.11 (-8.40%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$1.21 +0.01 (+0.83%) As of 06/27/2025 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACRV vs. ALEC, ACOG, INMB, ACTU, CGEN, FATE, KYTX, BDTX, VXRT, and LXEOShould you be buying Acrivon Therapeutics stock or one of its competitors? The main competitors of Acrivon Therapeutics include Alector (ALEC), Alpha Cognition (ACOG), INmune Bio (INMB), Actuate Therapeutics (ACTU), Compugen (CGEN), Fate Therapeutics (FATE), Kyverna Therapeutics (KYTX), Black Diamond Therapeutics (BDTX), Vaxart (VXRT), and Lexeo Therapeutics (LXEO). These companies are all part of the "pharmaceutical products" industry. Acrivon Therapeutics vs. Its Competitors Alector Alpha Cognition INmune Bio Actuate Therapeutics Compugen Fate Therapeutics Kyverna Therapeutics Black Diamond Therapeutics Vaxart Lexeo Therapeutics Acrivon Therapeutics (NASDAQ:ACRV) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation. Do insiders & institutionals believe in ACRV or ALEC? 71.6% of Acrivon Therapeutics shares are owned by institutional investors. Comparatively, 85.8% of Alector shares are owned by institutional investors. 11.9% of Acrivon Therapeutics shares are owned by insiders. Comparatively, 9.1% of Alector shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has better valuation and earnings, ACRV or ALEC? Acrivon Therapeutics has higher earnings, but lower revenue than Alector. Alector is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcrivon TherapeuticsN/AN/A-$80.56M-$2.22-0.54Alector$100.56M1.47-$119.05M-$1.26-1.17 Does the media refer more to ACRV or ALEC? In the previous week, Acrivon Therapeutics and Acrivon Therapeutics both had 2 articles in the media. Acrivon Therapeutics' average media sentiment score of 0.94 beat Alector's score of 0.44 indicating that Acrivon Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Acrivon Therapeutics Positive Alector Neutral Which has more volatility and risk, ACRV or ALEC? Acrivon Therapeutics has a beta of 1.55, suggesting that its share price is 55% more volatile than the S&P 500. Comparatively, Alector has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500. Is ACRV or ALEC more profitable? Acrivon Therapeutics has a net margin of 0.00% compared to Alector's net margin of -139.74%. Acrivon Therapeutics' return on equity of -44.66% beat Alector's return on equity.Company Net Margins Return on Equity Return on Assets Acrivon TherapeuticsN/A -44.66% -40.94% Alector -139.74%-100.58%-25.15% Do analysts rate ACRV or ALEC? Acrivon Therapeutics presently has a consensus target price of $17.71, indicating a potential upside of 1,376.19%. Alector has a consensus target price of $4.00, indicating a potential upside of 170.27%. Given Acrivon Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Acrivon Therapeutics is more favorable than Alector.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acrivon Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00Alector 2 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.14 SummaryAcrivon Therapeutics beats Alector on 11 of the 15 factors compared between the two stocks. Get Acrivon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACRV vs. The Competition Export to ExcelMetricAcrivon TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$41.08M$2.67B$5.48B$8.87BDividend YieldN/A1.64%5.35%4.15%P/E Ratio-0.549.3326.2119.66Price / SalesN/A394.49386.95105.10Price / CashN/A156.1136.4056.81Price / Book0.214.737.905.44Net Income-$80.56M$31.15M$3.16B$249.37M7 Day Performance1.69%21.65%3.08%3.96%1 Month Performance9.09%25.46%6.02%5.27%1 Year Performance-79.31%2.65%32.06%17.06% Acrivon Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACRVAcrivon Therapeutics2.8478 of 5 stars$1.20-8.4%$17.71+1,376.2%-79.2%$41.08MN/A-0.5458High Trading VolumeALECAlector3.8398 of 5 stars$1.38-6.5%$4.00+190.9%-67.4%$146.99M$100.56M-1.09270ACOGAlpha Cognition2.2961 of 5 stars$9.00-1.7%$20.00+122.2%N/A$146.74MN/A-7.50N/ANews CoveragePositive NewsINMBINmune Bio2.0313 of 5 stars$6.22-2.5%$22.80+266.6%-38.7%$146.64M$10K-3.2210Trending NewsGap UpHigh Trading VolumeACTUActuate Therapeutics2.0085 of 5 stars$7.05-5.6%$20.50+190.8%N/A$146.56MN/A0.0010Gap UpCGENCompugen2.2755 of 5 stars$1.63-0.6%$4.00+145.4%-5.7%$146.35M$27.86M-10.1970FATEFate Therapeutics4.1513 of 5 stars$1.14-4.2%$3.83+236.3%-68.1%$136.38M$13.63M-0.77550Analyst DowngradeKYTXKyverna Therapeutics2.1235 of 5 stars$3.22+4.9%$18.50+474.5%-55.4%$132.68M$7.03M-0.9596News CoveragePositive NewsBDTXBlack Diamond Therapeutics3.038 of 5 stars$2.27-2.6%$14.60+543.2%-50.0%$132.49MN/A37.8390Positive NewsGap UpVXRTVaxart2.146 of 5 stars$0.56-3.4%$3.00+435.3%-25.8%$132.42M$28.70M-2.08120Positive NewsLXEOLexeo Therapeutics2.1301 of 5 stars$3.96+1.3%$16.60+319.2%-72.3%$129.80M$650K-1.2058Positive News Related Companies and Tools Related Companies Alector Competitors Alpha Cognition Competitors INmune Bio Competitors Actuate Therapeutics Competitors Compugen Competitors Fate Therapeutics Competitors Kyverna Therapeutics Competitors Black Diamond Therapeutics Competitors Vaxart Competitors Lexeo Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACRV) was last updated on 6/28/2025 by MarketBeat.com Staff From Our PartnersNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acrivon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ACRV Stock Free ACRV Stock Alerts